Cargando…

The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders

Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential d...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Zubaidi, Hanaan Kareem, Hughes, Stephen Fôn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563807/
https://www.ncbi.nlm.nih.gov/pubmed/37822353
http://dx.doi.org/10.3389/bjbs.2023.11573
_version_ 1785118413793787904
author Al-Zubaidi, Hanaan Kareem
Hughes, Stephen Fôn
author_facet Al-Zubaidi, Hanaan Kareem
Hughes, Stephen Fôn
author_sort Al-Zubaidi, Hanaan Kareem
collection PubMed
description Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. Methods: A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017–2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. Results: All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. Conclusion: CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.
format Online
Article
Text
id pubmed-10563807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105638072023-10-11 The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders Al-Zubaidi, Hanaan Kareem Hughes, Stephen Fôn Br J Biomed Sci Health Archive Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. Methods: A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017–2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. Results: All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. Conclusion: CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them. Frontiers Media S.A. 2023-09-26 /pmc/articles/PMC10563807/ /pubmed/37822353 http://dx.doi.org/10.3389/bjbs.2023.11573 Text en Copyright © 2023 Al-Zubaidi and Hughes. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Al-Zubaidi, Hanaan Kareem
Hughes, Stephen Fôn
The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title_full The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title_fullStr The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title_full_unstemmed The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title_short The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
title_sort use of cd200 in the differential diagnosis of b-cell lymphoproliferative disorders
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563807/
https://www.ncbi.nlm.nih.gov/pubmed/37822353
http://dx.doi.org/10.3389/bjbs.2023.11573
work_keys_str_mv AT alzubaidihanaankareem theuseofcd200inthedifferentialdiagnosisofbcelllymphoproliferativedisorders
AT hughesstephenfon theuseofcd200inthedifferentialdiagnosisofbcelllymphoproliferativedisorders
AT alzubaidihanaankareem useofcd200inthedifferentialdiagnosisofbcelllymphoproliferativedisorders
AT hughesstephenfon useofcd200inthedifferentialdiagnosisofbcelllymphoproliferativedisorders